We are excited to announce that Lemna Bio, a standout company from the DayOne Accelerator 2025 cohort, is the first startup selected to join DayOne NEXT, our long-term support program for the most promising DayOne founders.
DayOne NEXT reflects a simple belief: the journey doesn’t end with the accelerator – it’s just the beginning. Designed as a hands-on, long-term venture builder, the program supports a small number of exceptional startups as they build, scale and anchor their R&D in the Basel Area. Participants receive a non-dilutive CHF 50,000 grant, up to 12 months of tailored operational and strategic support (valued at up to CHF 50,000), workspace at the Switzerland Innovation Park Basel Area, and deep integration into the region’s world-leading life sciences ecosystem.
By working side-by-side with founders, DayOne NEXT provides not just resources, but sustained, highly personalized support – from fractional expertise and mentorship to ecosystem access and visibility opportunities – helping startups transition from early traction to long-term impact.
Lemna Bio is a techbio company building a structural AI platform to decode and validate hard intracellular targets. While advances in chemistry are unlocking new ways to engage biological targets, failures in drug discovery are still largely driven by incorrect target selection or an incomplete understanding of how to engage them in a disease context. Lemna Bio develops the tools, intelligence and experimental data to help drug discovery teams de-risk target biology and disease mechanisms early – before committing to costly chemistry efforts.
Commenting on the milestone, Moustafa Houmani, Co-founder & CEO of Lemna Bio, said, “DayOne provided us with rare, first-hand insights into how pharmaceutical companies operate – insights that typically take years to acquire. Being selected for DayOne NEXT is an exciting opportunity to continue building with the right support and ecosystem around us.”
With Lemna Bio as the first company in DayOne NEXT, we are proud to deepen our commitment to the most promising founders in our community and to support them as they scale breakthrough innovations at the intersection of technology and pharma R&D.
